Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.
- Iovance Biotherapeutics stock is building positive momentum. Why is IOVA stock advancing?
Spillover Sentiment from Melanoma Breakthroughs
While Iovance has not released major news this week, investor enthusiasm has been fueled by positive readout data in the advanced skin cancer sector. Recent interim Phase 3 results from Moderna Inc. and Merck & Co. Inc. demonstrated statistically significant improvements in survival metrics for individualized melanoma treatments.
The positive readouts have reinforced market confidence in advanced melanoma therapies, directly benefiting Iovance as it commercializes its own FDA-approved, one-time cell therapy, Amtagvi.
Strong Earnings and Commercial Execution
The stock’s recent strength is further backed by solid fundamental performance. In its second-quarter financial report, Iovance beat expectations with $99.31 million in sales, driven by $91 million in U.S. Amtagvi revenue, and a narrower-than-expected loss of 11 cents per share.
Management reaffirmed full-year 2026 sales guidance of $350 million to $370 million, prompting several Wall Street analysts to raise their price targets.
Iovance Biotherapeutics Technical Levels To Watch
IOVA is still in a steep uptrend, with price at $9.18 sitting well above every major moving average: the 20-day SMA ($5.89), 50-day SMA ($4.95), 100-day SMA ($4.33), and 200-day SMA ($3.60). That kind of separation typically signals strong trend control, but it also raises the odds of sharper pullbacks if buyers pause.
RSI is the key momentum tell right now, and at 83.29 it’s firmly overbought—meaning the move is stretched and more vulnerable to consolidation or a fast dip even if the bigger trend stays bullish. The golden cross that formed in January (50-day SMA moving above the 200-day SMA) reinforces that the longer-term trend has been pointing higher for months.
- Key Resistance: $9.36 — the 52-week high area from August, where breakouts often need follow-through volume to stick
- Key Support: $5.89 — near the 20-day SMA, a level that often acts as the first “trend support” during pullbacks
IOVA Stock Price Movement Friday Morning
IOVA Stock Price Activity: Iovance Biotherapeutics shares were down 0.67% at $8.93 on Friday, according to Benzinga Pro data.
Image: Shutterstock
